Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest T Hawk

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2004
Irreversible ototoxicity associated with difluoromethylornithineChristopher D Lao, Patricia Backoff, Lawrence I Shotland, et al.
Clinical Therapeutics|March 6, 2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placeboNadir Arber, David Lieberman, Timothy C Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2004
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patientsFrank A Sinicrope, Elizabeth Half, Jeffrey S Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2012
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patientsMoubin Lin, Jian Gu, Cathy Eng, et al.
Oncotarget|June 25, 2019
Functional characterization of <i>CNOT3</i> variants identified in familial adenomatous polyposis adenomasRichard Glenn C Delacruz, Imelda T Sandoval, Kyle Chang, et al.
Cancer Research|April 17, 2004
Serum proteomic profiles suggest celecoxib-modulated targets and response predictorsZhen Xiao, Brian T Luke, Grant Izmirlian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese populationNina Joshi, Laura Lee Johnson, Wen-Qiang Wei, et al.
Cancer Research|July 5, 2006
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese populationNina Joshi, Laura Lee Johnson, Wen-Qiang Wei, et al.
Msystems|April 28, 2022
Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South TexasSuet-Ying Kwan, Caroline M Sabotta, Aron Joon, et al.
Gut Microbes|September 6, 2024
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolismSuet-Ying Kwan, Kristyn A Gonzales, Mohamed A Jamal, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 13, 2004
Irreversible ototoxicity associated with difluoromethylornithineChristopher D Lao, Patricia Backoff, Lawrence I Shotland, et al.
Clinical Therapeutics|March 6, 2012
The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placeboNadir Arber, David Lieberman, Timothy C Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 9, 2004
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patientsFrank A Sinicrope, Elizabeth Half, Jeffrey S Morris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2012
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patientsMoubin Lin, Jian Gu, Cathy Eng, et al.
Oncotarget|June 25, 2019
Functional characterization of <i>CNOT3</i> variants identified in familial adenomatous polyposis adenomasRichard Glenn C Delacruz, Imelda T Sandoval, Kyle Chang, et al.
Cancer Research|April 17, 2004
Serum proteomic profiles suggest celecoxib-modulated targets and response predictorsZhen Xiao, Brian T Luke, Grant Izmirlian, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 17, 2006
Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese populationNina Joshi, Laura Lee Johnson, Wen-Qiang Wei, et al.
Cancer Research|July 5, 2006
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese populationNina Joshi, Laura Lee Johnson, Wen-Qiang Wei, et al.
Msystems|April 28, 2022
Gut Microbiome Alterations Associated with Diabetes in Mexican Americans in South TexasSuet-Ying Kwan, Caroline M Sabotta, Aron Joon, et al.
Gut Microbes|September 6, 2024
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolismSuet-Ying Kwan, Kristyn A Gonzales, Mohamed A Jamal, et al.
Pageof 10